-
公开(公告)号:US20180318421A1
公开(公告)日:2018-11-08
申请号:US15589887
申请日:2017-05-08
IPC分类号: A61K45/00 , A61K31/192 , A61K31/197 , A61K31/198
CPC分类号: A61K45/05 , A61K31/192 , A61K31/197 , A61K31/198 , A61K2121/00 , A61K2300/00
摘要: Methods for the treatment of cancer, including glioblastoma multiforme (GBM) and recurrent glioblastoma multiforme (RGBM). The method includes administering to a patient a plurality of extraneous antineoplastons and a plurality of targeted agents. The plurality of extraneous antineoplastons may include two or more antineoplastons selected from phenylacetylglutaminate sodium (PG), phenylacetylisoglutaminate sodium (iso-PG), and phenylacetate (PN). The plurality of targeted agents may include two or more agents selected from bevacizumab, pazopanib, sorafenib, dasatinib, and everolimus.
-
公开(公告)号:US20180318287A1
公开(公告)日:2018-11-08
申请号:US15772118
申请日:2016-11-02
申请人: ASTRAZENECA AB
IPC分类号: A61K31/4745 , A61P35/00
CPC分类号: A61K31/4745 , A61K31/282 , A61K31/407 , A61K31/704 , A61K33/24 , A61K45/06 , A61K2121/00 , A61K2300/00 , A61P35/00 , C07D471/04
摘要: The specification generally relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, where x, R1, R2, R3, R4 and R5 have any of the meanings defined herein. The specification also relates to the use of compounds of Formula (I) and salts thereof to treat or prevent ATM mediated disease, including cancer. The specification further relates to pharmaceutical compositions comprising substituted imidazo[4,5-c]quinolin-2-one compounds and pharmaceutically acceptable salts thereof; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; and intermediates useful in such manufacture.
-
公开(公告)号:US20180312490A1
公开(公告)日:2018-11-01
申请号:US15963122
申请日:2018-04-26
申请人: AstraZeneca AB
发明人: Jason KETTLE , Stuart Pearson , Martin Packer , James Smith , Tudor Grecu
IPC分类号: C07D403/12 , C07D405/14 , A61P35/00
CPC分类号: C07D403/12 , A61K2121/00 , A61P35/00 , C07D405/14
摘要: The invention concerns compounds of Formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, R3 and R4 have any of the meanings hereinbefore defined in the description; process for their preparation; pharmaceutical compositions containing them and their use in treating KIT mediated diseases.
-
公开(公告)号:US10011633B2
公开(公告)日:2018-07-03
申请号:US15726071
申请日:2017-10-05
申请人: Albireo AB
IPC分类号: A61K31/554 , A61K31/575 , A61K38/05 , C07K5/065 , C07K5/062 , A61K38/00
CPC分类号: C07K5/06078 , A61K31/55 , A61K31/554 , A61K31/575 , A61K38/00 , A61K38/05 , A61K2121/00 , C07K5/06026 , C07K5/0606
摘要: The present invention regards specific IBAT inhibitors useful in the prophylaxis and/or treatment of a liver disease. It also relates to compositions comprising these IBAT inhibitors, a method for treatment of the disorders and a kit comprising the substances or the compositions.
-
公开(公告)号:US20180169257A1
公开(公告)日:2018-06-21
申请号:US15739363
申请日:2016-06-30
发明人: Timothy Lewis , Lori Westendorf , Django Sussman , Che-Leung Law
CPC分类号: A61K47/6803 , A61K47/65 , A61K47/6811 , A61K47/6851 , A61K2039/505 , A61K2039/572 , A61K2121/00 , A61P35/00 , C07K16/2803 , C07K2317/24 , C07K2317/33 , C07K2317/567 , C07K2317/73 , C07K2317/732 , C07K2317/92
摘要: Disclosed are antibodies, including antibody drug conjugates, that specifically bind to NTB-A. Also disclosed are methods for using the anti-NTB-A antibodies to detect or modulate activity of (e.g., inhibit proliferation of) an NTB-A-expressing cell, as well as for diagnoses or treatment of diseases or disorders (e.g., cancer) associated with NTB-A-expressing cells, such as multiple myeloma, non-Hodgkin lymphoma and acute myeloid leukemia.
-
公开(公告)号:US09982051B2
公开(公告)日:2018-05-29
申请号:US15821678
申请日:2017-11-22
IPC分类号: C07K16/28 , A61K39/395 , A61K31/7068 , A61K38/00 , A61K38/18 , A61K38/16 , A61K38/02 , A61K45/06 , A61K31/4155 , A61K38/14 , A61K38/20 , A61K33/36 , A61K31/404 , A61K39/00
CPC分类号: C07K16/2803 , A61K31/404 , A61K31/4155 , A61K31/7068 , A61K33/36 , A61K38/00 , A61K38/005 , A61K38/02 , A61K38/14 , A61K38/168 , A61K38/18 , A61K38/208 , A61K39/395 , A61K39/39541 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61K2039/545 , A61K2039/57 , A61K2039/572 , A61K2121/00 , C07K16/2818 , C07K16/2827 , C07K2317/21 , C07K2317/24 , C07K2317/75 , C07K2317/76 , A61K2300/00
摘要: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.
-
7.
公开(公告)号:US09982050B2
公开(公告)日:2018-05-29
申请号:US15821672
申请日:2017-11-22
IPC分类号: C07K16/28 , A61K39/395 , A61K38/16 , A61K31/7068 , A61K45/06 , A61K38/18 , A61K38/14 , A61K38/00 , A61K38/20 , A61K33/36 , A61K31/404 , A61K31/4155 , A61K39/00
CPC分类号: C07K16/2803 , A61K31/404 , A61K31/4155 , A61K31/7068 , A61K33/36 , A61K38/00 , A61K38/005 , A61K38/02 , A61K38/14 , A61K38/168 , A61K38/18 , A61K38/208 , A61K39/395 , A61K39/39541 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61K2039/545 , A61K2039/57 , A61K2039/572 , A61K2121/00 , C07K16/2818 , C07K16/2827 , C07K2317/21 , C07K2317/24 , C07K2317/75 , C07K2317/76 , A61K2300/00
摘要: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.
-
8.
公开(公告)号:US09982048B2
公开(公告)日:2018-05-29
申请号:US15821595
申请日:2017-11-22
IPC分类号: C07K16/28 , A61K39/395 , A61K38/16 , A61K31/7068 , A61K45/06 , A61K38/18 , A61K38/14 , A61K38/00 , A61K38/20 , A61K33/36 , A61K31/404 , A61K31/4155 , A61K39/00
CPC分类号: C07K16/2803 , A61K31/404 , A61K31/4155 , A61K31/7068 , A61K33/36 , A61K38/00 , A61K38/005 , A61K38/02 , A61K38/14 , A61K38/168 , A61K38/18 , A61K38/208 , A61K39/395 , A61K39/39541 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61K2039/545 , A61K2039/57 , A61K2039/572 , A61K2121/00 , C07K16/2818 , C07K16/2827 , C07K2317/21 , C07K2317/24 , C07K2317/75 , C07K2317/76 , A61K2300/00
摘要: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.
-
公开(公告)号:US09938302B2
公开(公告)日:2018-04-10
申请号:US15599401
申请日:2017-05-18
申请人: Bio TheryX, Inc.
发明人: Kyle W. H. Chan , Leah Fung , Robert Sullivan , Paul E. Erdman , Frank Mercurio , Eduardo Torres
IPC分类号: C07D513/16 , C07D487/00 , C07D403/04 , C07D409/14 , C07D247/02 , C07D225/02 , C07C223/02 , C07D221/00 , C07D209/00 , C07D207/04 , A61K38/00 , A61K31/437 , A61K39/00
CPC分类号: C07D513/16 , A61K9/0014 , A61K9/0019 , A61K9/0043 , A61K9/0048 , A61K9/0053 , A61K9/006 , A61K9/007 , A61K9/0078 , A61K9/06 , A61K9/08 , A61K9/20 , A61K9/48 , A61K9/7023 , A61K31/40 , A61K31/437 , A61K31/55 , A61K38/00 , A61K47/55 , A61K2039/505 , A61K2121/00 , C07C223/02 , C07D207/04 , C07D209/00 , C07D221/00 , C07D225/02 , C07D247/02 , C07D401/14 , C07D403/04 , C07D403/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/14 , C07D487/00 , C07D513/14
摘要: The present invention provides chimeric compounds that modulate protein function, to restore protein homeostasis, including cytokine, aiolos, and/or ikaros activity, TNF-alpha activity, CK1-alpha activity and cell-cell adhesion. The invention provides methods of modulating protein-mediated diseases, such as cytokine-mediated diseases, disorders, conditions, or responses. Compositions, including in combination with other cytokine and inflammatory mediators, are provided. Methods of treatment, amelioration, or prevention of protein-mediated diseases, disorders, and conditions, such as cytokine-mediated diseases, disorders, and conditions, including inflammation, fibromyalgia, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, inflammatory bowel diseases, Crohn's disease, ulcerative colitis, uveitis, inflammatory lung diseases, chronic obstructive pulmonary disease, Alzheimer's disease, organ transplant rejection, and cancer, are provided.
-
公开(公告)号:US20180050012A1
公开(公告)日:2018-02-22
申请号:US15671183
申请日:2017-08-08
IPC分类号: A61K31/341 , C07D307/20 , A61K31/122
CPC分类号: A61K31/341 , A61K31/122 , A61K31/365 , A61K31/513 , A61K31/555 , A61K33/24 , A61K45/06 , A61K2121/00 , A61K2300/00 , C07D307/20
摘要: The present invention is directed to a method for inhibiting growth of ovarian cancer cells in a subject in need thereof, comprising administering to said subject a composition comprising an effective amount of 4-acetyl-antroquinonol B or a pharmaceutical acceptable salt thereof, and a pharmaceutically acceptable carrier.
-
-
-
-
-
-
-
-
-